Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Nearly two dozen clinical trials targeting the immune system are in clinical trials for Alzheimer's disease.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
Slowdown in progress found with cancer survival in England and Wales
2.
How the skin cancer virus outperforms the replication of host cells.
3.
The September 2018 issue of Medical Bulletin.
4.
From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.
5.
Predicting adult mortality from oral cancer using a machine learning approach.
1.
Clinical Analysis of Prostate Cancer
2.
Exploring the Latest Treatments for Essential Thrombocythemia
3.
The Basics of M.C.V Normal Range for Better Health Management
4.
Molecular & Genetic Oncology: Emerging Frontiers in 2025
5.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
5.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge